Rhythm Pharmaceuticals plans sale of 57,000 shares

Rhythm Pharmaceuticals has a planned sale of 57,000 shares of its common stock through Morgan Stanley Smith Barney LLC Executive Financial Services on August 12, 2026.

Rhea-AI Filing Summary

Rhythm Pharmaceuticals has a planned sale of 57,000 shares of its common stock through Morgan Stanley Smith Barney LLC Executive Financial Services on August 12, 2026. The shares have an aggregate market value of $6,432,165.00 and are listed on NASDAQ. The sale includes 46,625 shares issuable from the exercise of stock options dated August 12, 2026, and 10,375 shares from restricted stock units dated April 14, 2024.

Key Figures

Shares planned for sale: 57,000 shares Aggregate market value: $6,432,165.00 Option shares: 46,625 shares +2 more

5 metrics

Shares planned for sale 57,000 shares Common stock to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services

Aggregate market value $6,432,165.00 Market value of 57,000 shares of common stock

Option shares 46,625 shares Shares underlying stock options dated August 12, 2026

RSU shares 10,375 shares Shares associated with restricted stock units dated April 14, 2024

Planned sale date 08/12/2026 Date associated with the common stock sale and option exercise

Key Terms

Form 144, Exercise of Stock Options, Restricted Stock Units, aggregate market value

4 terms

Form 144 regulatory

"144: Securities Information Common | Morgan Stanley Smith Barney"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

Exercise of Stock Options financial

"Common | 08/12/2026 | Exercise of Stock Options | Issuer"

Restricted Stock Units financial

"Common | 04/14/2024 | Restricted Stock Units | Issuer"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

aggregate market value financial

"Common | Morgan Stanley Smith Barney LLC ... | 6432165.00"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stock sale is disclosed for Rhythm Pharmaceuticals (RYTM)?

Rhythm Pharmaceuticals has a planned sale of 57,000 shares of common stock with an aggregate market value of $6,432,165.00, to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services.

How many Rhythm Pharmaceuticals (RYTM) shares come from stock options?

The planned transaction includes 46,625 shares of Rhythm Pharmaceuticals common stock issuable from the exercise of stock options with a transaction date of August 12, 2026.

How many Rhythm Pharmaceuticals (RYTM) shares come from RSUs?

The planned sale includes 10,375 shares of Rhythm Pharmaceuticals common stock associated with restricted stock units dated April 14, 2024, contributing to the total 57,000 shares indicated.

What is the aggregate market value of the Rhythm Pharmaceuticals (RYTM) shares to be sold?

The total planned sale represents an aggregate market value of $6,432,165.00 for 57,000 shares of Rhythm Pharmaceuticals common stock listed on NASDAQ.

When is the planned sale date for the Rhythm Pharmaceuticals (RYTM) shares?

The common stock sale for Rhythm Pharmaceuticals is associated with a transaction date of August 12, 2026, including shares from both stock option exercises and restricted stock units.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/12/2026 - 04:34 PM Accepted by SEC EDGAR 08/12/2026 - 04:34 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001774702
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	RHYTHM PHARMACEUTICALS, INC.
SEC File Number	001-38223
Address of Issuer	222 Berkeley Street, 12th Floor BOSTON MASSACHUSETTS 02116
Phone	8572644280
Name of Person for Whose Account the Securities are To Be Sold	YANN MAZABRAUD
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	57000	6432165.00	68852082	08/12/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/12/2026	Exercise of Stock Options	Issuer			46625	08/12/2026	Cash
Common	04/14/2024	Restricted Stock Units	Issuer			10375	04/14/2024	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	08/12/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	05/13/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Yann Mazabraud
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)